Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II clinical study of CP-COV03 for COVID-19

Next Previous
X
Search
Trial Profile

Phase II clinical study of CP-COV03 for COVID-19

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 21 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Niclosamide (Primary)
  • Indications COVID 2019 infections
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Hyundai Bioscience

    • Most Recent Events

    • 17 Jun 2023 Results presented in a Hyundai Bioscience media release.
    • 17 Jun 2023 According to a Hyundai Bioscience media release, result of Xafty's clinical study was presented at Emerging Science Session of the American Society for Microbiology (ASM) Microbe 2023, held in Houston, Texas, on June 17, 2023.
    • 03 May 2023 Status changed from recruiting to completed, according to a Hyundai Bioscience media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top